Retigabine (ezogabine in the USA) was approved as an anti-seizure drug in Europe and the USA in 2010. It is a potassium-channel facilitator and unique in its mechanism of action. Absorption is not affected by food and kinetics are linear; drug interactions are mini-mal. Clinical trials demonstrated efficacy in partial seizures, and approval is for the adjunctive treatment of partial-onset seizures in adults. Doses range from 600 to 1200 mg/day, with 900 mg/day expected to be the median. The current dosage form requires three-times-per-day administration, and the dose must be titrated in most patients. Most adverse effects are dose-related and include dizziness, somnolence, blurred vision, confusion, and dysarthria. Bladder dysfunction, mostly mild and related to the drug’s mechanism of action, was observed in 8-9% of patients in the clinical trials.